【드래곤 스포츠】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 뉴스 : 안구정화

로그인

글쓰기

[IT뉴스]'iCure' Signs $30.5 Million Patch Supply Deal With Canadian Pharma Honessan

온카뱅크관리자

2025-03-25 15:17:32

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
         <section dmcf-sid="GYwWyv5rsJ">
          <p contents-hash="58491ce675c1875a3accb40028d295529d3be0ccfdb6d0252ef75592543b0d59" dmcf-pid="HebRMQLKwd" dmcf-ptype="general"> [Seungkwon Kim, Edaily Reporter] South Korean pharmaceutical company iCure announced it has signed a five-year supply agreement worth approximately 40.9 billion won ($30.5 million) with Canadian firm Honessan Pharma for topical patch formulations of lidocaine, ketoprofen, and loxoprofen. The patches will be distributed across the Middle East under the terms of the deal.</p>
          <p contents-hash="57608326e2226ead6e6d78d83e231541c35eefbf226c338f435da32d2f87d059" dmcf-pid="XdKeRxo9Ee" dmcf-ptype="general">This marks the largest overseas topical patch supply deal in iCure’s history. On an annual average basis, the contract equates to around 8.2 billion won ($6.1 million) in revenue, nearly 62% of iCure’s 2024 sales from its core patch and topical CDMO (Contract Development and Manufacturing Organization) business, which totaled 13.1 billion won. It also represents about 34% of the company’s total 2024 pharmaceutical revenue of 23.9 billion won.</p>
          <figure class="figure_frm origin_fig" contents-hash="88e848a634b96a47c08cf939ffb42d6b54f5cca5157b53f447eb5e9c53c3def1" dmcf-pid="ZJ9deMg2IR" dmcf-ptype="figure">
           <p class="link_figure"><img class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202503/25/Edaily/20250325150854078vnzq.jpg" data-org-width="383" dmcf-mid="YiqxQ6iBwi" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202503/25/Edaily/20250325150854078vnzq.jpg" width="658"></p>
          </figure>
          <div contents-hash="79fb62c33312773d750739b0d6d6200858a71dbc89f033446f957762748ac5c8" dmcf-pid="5i2JdRaVwM" dmcf-ptype="general">
           With this latest deal, iCure’s cumulative overseas pharmaceutical supply contracts over the past two years now total roughly 300 billion won ($224 million), based on recent exchange rates.
          </div>
          <p contents-hash="1e08757a2abcd12e930263bac8176a729615d6bfb90dbf7d09da7f3370df20ea" dmcf-pid="1nViJeNfOx" dmcf-ptype="general">Of that total, the donepezil patch accounts for the largest portion. The product, initially licensed to Italy’s Menarini, has expanded to cover 43 countries across Southeast Asia, Latin America, the Middle East, and Africa, securing deals worth about 240 billion won, including upfront and milestone payments. Meanwhile, topical patches including the new deal with Honessan have secured contracts in 40 countries across similar regions, totaling approximately 58.2 billion won.</p>
          <p contents-hash="4dd9e6b0fc900bcf6e6d7a08dbbf03586de8802204e480f967d3f4247e928bd5" dmcf-pid="tLfnidj4DQ" dmcf-ptype="general">The company expects these accumulated contracts to transition iCure’s pharma business from a domestic-focused sales structure to one increasingly driven by exports. To commercialize the supply deals, iCure is currently collaborating with each partner on obtaining local regulatory approvals.</p>
          <p contents-hash="61d93fa65b1d409221d326a86a19cb6441039d98d5d0cd13b06275c272f2bed3" dmcf-pid="Fo4LnJA8rP" dmcf-ptype="general">“When I became CEO three years ago, I was convinced that expanding our pharmaceutical business beyond the limited domestic market was essential for long-term profitability,” said iCure CEO Lee Young-seok. “Since then, we’ve focused on signing overseas CDMO contracts for our core patch and topical formulations. I’m proud that our efforts have led to cumulative deals worth nearly 300 billion won. We will now accelerate exports, boost our factory utilization, and continue to drive revenue growth and profitability.” He added.</p>
          <p contents-hash="fa185dfa66174f3862720ff5e7c6a670447ea81f31f03cce2b431f4bdbcf1b49" dmcf-pid="3g8oLic6E6" dmcf-ptype="general">김승권 (peace@edaily.co.kr) </p>
         </section> 
        </div> 
        <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>

댓글 총 0개

이번주 포인트랭킹

매주 일요일 밤 0시에 랭킹을 초기화합니다.

14,000상품권
23,000상품권
32,000상품권

업체홍보/구인 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기